IMMX
Immix Biopharma, Inc.Company Information
- Company Name
- Immix Biopharma, Inc.
- CIK
- CIK0001873835
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- IMMX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- IMMX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-10
- Last sale
- —
- Shares purchased (TTM)
- 51,019
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 54,555,334
- Shares outstanding
- 63,771,377
- Ownership
- 85.55%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- 43.42%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 225 | 79 | 94 | 16 | 12 | 16 | 18 | 20 | 24 | 29 | 18 | 20 | ||||||
| Income Tax Receivable | - | 0 | - | - | - | - | 2 | 2 | 2 | 2 | 1 | 1 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 234 | 92 | 101 | 17 | 12 | 17 | 20 | 23 | 27 | 33 | 20 | 22 | ||||||
| Short Term Investments | 7 | 11 | 6 | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | ||||||
| Deferred Costs | - | 0 | 0 | 0 | 0 | - | - | - | - | - | 0 | - | ||||||
| Long Term Investments | 2 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | ||||||
| Property Plant And Equipment Net | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | ||||||
| Assets | 239 | 96 | 105 | 20 | 16 | 20 | 23 | 25 | 29 | 34 | 20 | 22 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 9 | 10 | 10 | 11 | 10 | 9 | 9 | 7 | 4 | 6 | 4 | 3 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 9 | 11 | 10 | 11 | 10 | 9 | 9 | 7 | 4 | 6 | 4 | 3 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | ||||||
| Liabilities | 10 | 11 | 11 | 12 | 11 | 10 | 10 | 8 | 5 | 7 | 4 | 3 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 355 | 199 | 198 | 102 | 91 | 89 | 88 | 88 | 87 | 87 | 70 | 68 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Stockholders Equity | 229 | 84 | 94 | 8 | 5 | 10 | 13 | 18 | 24 | 28 | 16 | 20 | ||||||
| Retained Earnings Accumulated Deficit | -126 | -115 | -104 | -94 | -86 | -80 | -75 | -70 | -63 | -59 | -53 | -48 | ||||||
| Treasury Stock Value | - | - | - | - | - | - | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Treasury Stock Common Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | - | - | - | - | - | ||||||
| Minority Interest | - | - | - | - | - | - | - | - | - | -0 | -0 | -0 | ||||||
| Liabilities And Stockholders Equity | 239 | 96 | 105 | 20 | 16 | 20 | 23 | 25 | 29 | 34 | 20 | 22 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 72 | 53 | 53 | 33 | 28 | 28 | 28 | 28 | 28 | 26 | 20 | 20 | ||||||
| Shares Outstanding | 72 | 53 | 53 | 33 | 28 | 28 | 28 | 27 | 27 | 26 | 20 | 20 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialImmix Biopharma, Inc. (IMMX) — SEC Financial Statements & Analysis
Immix Biopharma, Inc. (IMMX) is a pharmaceutical preparations company, incorporated in DE. Immix Biopharma, Inc. trades on Nasdaq as: IMMX. Immix Biopharma, Inc. (IMMX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, Immix Biopharma, Inc. carries a market cap of $657.48M, a P/E ratio of -16.47x, a P/B ratio of 2.87x, an enterprise value of $431.99M, and an EV/EBITDA multiple of -10.41x. On profitability, it posts a Return on Equity (ROE) of -34.19% and a Return on Assets (ROA) of -31.35%. Per share, it reports EPS of $-0.63, diluted EPS of $-0.63, free cash flow per share of $-0.61, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 73.30% year-over-year and EPS growth of -18.52% year-over-year. On the balance sheet, it maintains a current ratio of 25.13x, a quick ratio of 24.95x, working capital of $224.49M, a debt-to-equity ratio of 0.04x, a debt ratio of 0.04, an interest coverage ratio of -29295.45x, free cash flow of $-39.09M (TTM), and net debt of $-225.49M. Figures sourced from SEC EDGAR.
- Market Cap
- $657.48M
- P/E TTM
- -16.47x
- EPS TTM
- $-0.63
- P/B TTM
- 2.87x
- ROE TTM
- -34.19%
- ROA TTM
- -31.35%
- Debt To Equity
- 0.04x
- Free Cash Flow TTM
- $-39.09M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Immix Biopharma, Inc. in?
Immix Biopharma, Inc. (IMMX) operates in the Pharmaceutical Preparations industry.
What exchange does IMMX trade on?
Immix Biopharma, Inc. (IMMX) trades on the Nasdaq.
Where is Immix Biopharma, Inc. incorporated?
Immix Biopharma, Inc. is incorporated in DE.
When was Immix Biopharma, Inc. (IMMX)'s most recent SEC filing?
Immix Biopharma, Inc. (IMMX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is IMMX's market cap?
Immix Biopharma, Inc. (IMMX) has a market capitalization of $657.48M as of 2026-06-30.
What is IMMX's EPS (earnings per share)?
Immix Biopharma, Inc. (IMMX)'s trailing twelve month EPS is $-0.63 as of 2026-06-30.
What is IMMX's ROE (return on equity)?
Immix Biopharma, Inc. (IMMX)'s trailing twelve month Return on Equity (ROE) is -34.19% as of 2026-06-30.
What is IMMX's ROA (return on assets)?
Immix Biopharma, Inc. (IMMX)'s trailing twelve month Return on Assets (ROA) is -31.35% as of 2026-06-30.
What is IMMX's EV/EBITDA?
Immix Biopharma, Inc. (IMMX)'s trailing twelve month EV/EBITDA is -10.41x as of 2026-06-30.